COMMUNIQUÉS West-GlobeNewswire
-
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
23/02/2026 -
ICU Medical to Participate in Upcoming Investor Conferences
23/02/2026 -
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
23/02/2026 -
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
23/02/2026 -
SafeSpace Global Corporation Transitions from Pre-Revenue to Active Revenue Generation with Eight Contracted Senior Living Facility Installations
23/02/2026 -
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
23/02/2026 -
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
23/02/2026 -
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
23/02/2026 -
Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
23/02/2026 -
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
23/02/2026 -
Bicara Therapeutics to Participate in Upcoming Investor Conferences
23/02/2026 -
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
23/02/2026 -
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
23/02/2026 -
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
23/02/2026 -
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved
23/02/2026 -
TOMI Environmental Solutions Receives Biocidal Product Approvals in Great Britain and Northern Ireland
23/02/2026 -
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
23/02/2026 -
RE+Vitalize Health and Nutrition Announces Initiative to Advance Clean and Transparent Supplement Standards
23/02/2026 -
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
23/02/2026
Pages